Mankind Pharma – Exclusive Insulin In-Licensing Deal

1.

has entered into an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical for the commercialisation of Insulin Degludec and Insulin Degludec + Aspart combination in India. The deal will expand Mankind’s injectable diabetes portfolio and strengthen its presence in the chronic-care/anti-diabetic segment. 2. Strategically positive for Mankind Pharma, as the company has been actively expanding its diabetes franchise through insulin and other chronic therapies. Mankind already markets insulin glargine and has been building capabilities around insulin aspart; its FY26 annual report specifically highlights Insulin Degludec and Insulin Aspart as part of its China in-licensing strategy. Why it matters * Insulin Degludec is a long-acting basal insulin, while the Degludec + Aspart combination provides basal-plus-mealtime insulin coverage. * The products address a large and growing diabetes market in India, giving Mankind an opportunity to deepen its presence in injectable diabetes therapies. * The agreement is consistent with Mankind’s strategy of leveraging global innovation through in-licensing rather than developing every product internally, potentially enabling faster portfolio expansion. * Financial terms and commercial launch timelines have not been disclosed, so the immediate revenue/profit contribution cannot yet be quantified. Overall: The announcement is strategically positive for Mankind Pharma, strengthening its diabetes franchise and adding differentiated insulin products. The key triggers going forward will be regulatory/commercial launch, pricing, doctor adoption and the pace at which the new products contribute to the company’s chronic-care revenues.